Posts Tagged ‘Lp-PLA2’

November 12th, 2013

Promising GSK Heart Drug Misses Primary Endpoint in 15,000-Patient Trial

GlaxoSmithKline announced today that the first of two pivotal phase 3 trials with a new drug, darapladib, had failed to meet its primary endpoint. Full results of the trial will be presented at a scientific meeting. The STABILITY trial (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY) tested the effect of darapladib, an investigational Lp-PLA2 inhibitor, in more than […]